← board
HROW
distress 1/10 · well-funded / low risk$42.12-2%today-23% from 52w high
Lead: procedural sedation
Revenue
$44M
Liquidity
$102M
Runway
—
Shares 1y
+1%
Price & events
-7.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-6.1%
1W
-1.5%
1M
+8.7%
3M
-5.3%
6M
+14.0%
1Y
+72.1%
2Y
+410.0%
5Y
+473.1%
All
Overview
- Market Cap
- $1.57B
- Enterprise Value
- $1.78B
- Volume
- 32.05K
- 52 Week Range
- $29.03 – $54.80
- Total Shares
- 37.28M
- Float Shares
- 28.28M
- Short %
- 21.35%
- % Held by Insiders
- 15.47%
- % Held by Institutions
- 58.88%
- RVOL
- 0.04x
- Beta
- 0.26
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 9
- H1 2028Guided 55%PDUFAPDUFAMELT-300 · Potential FDA approval in first half of 2028.SEC 8-K
- 2027Guided 40%regulatory submissionFiled (NDA/BLA)MELT-300 · Planned NDA submission to FDA for MELT-300SEC 8-K
- H1 2027Guided 55%regulatory submissionFiled (NDA/BLA)MELT-300 · Prepare and submit NDA for MELT-300.SEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-11-17partnershipMELT-300, MELT-210, MELT-400 · Completed acquisition of Melt Pharmaceuticals, adding pipeline of non-opioid sedation candidates.SEC 8-K
- 2025-11-10partnershipVEVYE · Partnership with Alto Pharmacy to expand VEVYE Access for All program capacitySEC 8-K
- 2025-09-24partnershipAgreement to acquire Melt PharmaceuticalsSEC 8-K
- 2025-07-17partnershipBYOOVIZ; OPUVIZ · Harrow gains exclusive U.S. commercial rights to ranibizumab-nuna and aflibercept-yszy biosimilars.SEC 8-K
- 2025-06-09partnershipBYQLOVI · Harrow acquired exclusive U.S. commercial rights from Formosa Pharmaceuticals for BYQLOVI.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $68 (+61% upside) · 8 analysts
- 2026-07-21BTIGBuy
- 2026-05-13Cantor FitzgeraldOverweight
- 2026-05-12BTIGBuy
- 2026-04-17BTIGBuy
- 2026-04-07B. Riley SecuritiesBuy
- 2026-03-19HC Wainwright & Co.Buy
Competitors — procedural sedation
- none identified
Recent news
- 2026-07-21HROW Reiterated by BTIG -- Price Target Maintained at $63.00 - GuruFocus
- 2026-07-21Harrow, Inc. (HROW) Stock Analysis: Strong Buy Ratings and 52% Potential Upside Drive Investor Interest - DirectorsTalk Interviews
- 2026-07-21Harrow Inc (HROW) Shares Fall 4.7% -- What GF Score of 80 Tells Investors - GuruFocus
- 2026-07-21Harrow Inc (HROW) Shares Fall 4.7% -- What GF Score of 80 Tells Investors - GuruFocus
- 2026-07-20Samsung Bioepis, Harrow present SB11 biosimilar study results By Investing.com - Investing.com Nigeria
- 2026-07-20Harrow (HROW) Unveils Positive Interim Data on SB11 at Retina Sp - GuruFocus
- 2026-07-20Harrow (HROW) Unveils Positive Interim Data on SB11 at Retina Sp - GuruFocus
- 2026-07-20Samsung Bioepis, Harrow present SB11 biosimilar study results - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.